{
    "2019-06-20": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Drugs Under FDA Review With Blockbuster Potential",
                "features": {
                    "keywords": [
                        "Drugs",
                        "FDA",
                        "Blockbuster"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Allergan Up As Analyst Statement Sparks Business Split Rumors",
                "features": {
                    "keywords": [
                        "Allergan",
                        "Analyst",
                        "Statement",
                        "Business Split"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-22",
                "original_text": "Opinion: Medical Marijuana Is a Terrible Investment",
                "features": {
                    "keywords": [
                        "Medical",
                        "Marijuana",
                        "Terrible",
                        "Investment"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "cannabis"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-06-18",
                "original_text": "Implied EPS Analyst Target Price: $36",
                "features": {
                    "keywords": [
                        "Implied",
                        "EPS",
                        "Analyst",
                        "Target Price"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}